Leadership

Chief Executive Officer

Brian Culley

Chief Financial Officer

Kevin L. Cook

General Counsel & Corporate Secretary

George A. Samuel III

Vice President, Business Development

Derek Kelaita

Sr. Vice President, Clinical and Medical Affairs

Gary S. Hogge, D.V.M., M.S. Ph.D.

Sr. Vice President, Global Head of R&D

François Binette, Ph.D.

Chief Executive Officer, Cell Cure Neurosciences

Rami Skaliter, M.Sc., Ph.D.

Chief Executive Officer

Brian Culley

Mr. Culley joined Lineage as Chief Executive Officer in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast’s merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast’s Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast’s Senior Vice President, Business Development, and from 2004 to 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. (NBIX). Mr. Culley has also served on the Board of Orphagen Pharmaceuticals, Inc. since May 2017. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University. Mr. Culley brings to our Board significant knowledge of the biotechnology industry and extensive experience as an executive and board member of publicly traded pharmaceutical companies.

Chief Financial Officer

Kevin L. Cook

Kevin Cook, B.S., M.B.A., most recently served as Chief Operating Officer of a family office investment firm with an emphasis in the solar energy and infrastructure industries, where he managed existing portfolio companies while pursuing new control investments. From 2012 to 2019, he served as Vice President of Corporate Development and Strategy and Vice President of Business Development for Breitburn GP LLC, where he led aggressive growth and diversification efforts for Breitburn Energy and affiliates. From 2000 to 2011, Mr. Cook served as an investment banker for Merrill Lynch & Co., where he advised life sciences companies and other clients across a range of industries in connection with corporate finance and strategic assignments. Mr. Cook earned his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his B.S. from the University of California, Davis.

General Counsel & Corporate Secretary

George A. Samuel III

Mr. Samuel joined Lineage as General Counsel and Corporate Secretary in September 2021. Prior to joining Lineage, Mr. Samuel most recently served as Director, Senior Counsel for Lytx, Inc., where he managed the commercial legal operations for an international video telematics SaaS company. Prior to that, Mr. Samuel served as VP, General Counsel and Corporate Secretary for Cardiff Oncology, Inc. (formerly known as Trovagene, Inc.), a clinical-stage biotechnology company focused on developing treatments in oncology. While at Cardiff Oncology, he advised on strategic, business development and operational decisions; oversaw capital raising efforts, regulatory compliance as well as SEC reporting; and managed intellectual property, including technology transfer and licensing. Mr. Samuel has also practiced corporate law at major law firms, including DLA Piper LLP and Cooley LLP, where he served as outside counsel to public and private companies in a variety of commercial transactions. Mr. Samuel received a J.D. from Columbia University School of Law, and a B.A. in Philosophy from Tufts University and is a member of the State Bar of California and New York.

Vice President, Business Development

Derek Kelaita

Derek Kelaita joined Lineage Cell Therapeutics as the Vice President, Business Development in August 2019.  Derek brings 20 years of experience with publicly-traded and venture-backed biotechnology companies to Lineage.  He was most recently Vice President of Business Development at ArmaGen from 2013 through early 2019, where he negotiated several early-stage research collaborations and option agreements with pharma partners related to the company’s blood-brain barrier technology as well as a $225M global license agreement with Shire plc (now part of Takeda Pharmaceuticals) for ArmaGen’s lead clinical stage program.  Throughout his career, Derek is responsible for licensing/M&A transactions cumulatively valued at over $1 billion in multiple therapeutic areas including:  Neurology (ArmaGen), Immunotherapy (AnaptysBio), Metabolic/diabetes (Cebix), Dental (Novalar), Infectious disease (Nventa), Oncology (Dendreon) and Cardiovascular disease (Corvas).  He began his career as a Research Associate at the Sanford Burnham Institute in La Jolla, CA.  Derek has a BA in Molecular and Cell Biology from the University of California, Berkeley and an MBA from University of San Diego.

Sr. Vice President, Clinical and Medical Affairs

Gary S. Hogge, D.V.M., M.S. Ph.D.

Dr. Hogge joined Lineage as Senior Vice President of Clinical and Medical Affairs in February 2018. Dr. Hogge has 20 years of experience developing and supporting the commercialization of a number of products over a broad range of therapeutic areas. Dr. Hogge has held a variety of roles of increasing responsibility across multiple therapeutic areas in both clinical development and medical affairs. Previously Dr. Hogge was the Vice President of Medical Affairs at Questcor Pharmaceuticals, Inc. (QCOR) and before that held multiple leadership roles in both clinical development and medical affairs at Elan Pharmaceuticals including various responsibilities in the global clinical development of Tysabri® (natalizumab) in Crohn’s disease and multiple sclerosis, and for building and leading the medical affairs function. He served as medical director following the approval and launch of Tysabri. Prior to those accomplishments, he worked in clinical development for Ceplene® (histamine dihydrochloride) at Maxim Pharmaceuticals and in the immunology research and development group at Pfizer. Dr. Hogge obtained his B.S. degree and D.V.M. from Colorado State University, his M.S. and Ph.D. from the University of Wisconsin-Madison and was a visiting scientist at the Queensland Institute of Medical Research (QIMR) in Brisbane, Australia.

Sr. Vice President, Global Head of R&D

François Binette, Ph.D.

François Binette, Ph.D. is Head of Global Development for Lineage. Dr. Binette has over 20 years of experience driving innovation in regenerative medicine therapy development. During his first industry appointment at Genzyme Tissue Repair in Cambridge, he helped pioneer Carticel™ for cartilage repair, the first FDA BLA-approved cell therapy product for human use. He then led R&D for Biosyntech, a startup biomaterials company in Montreal applying its proprietary platform for various tissue engineering and drug delivery applications. His systematic approach to demonstrating proof of principle in various indications brought numerous corporate partnership deals helping Biosyntech through a public offering. Dr. Binette then joined the DePuy Franchise of Johnson and Johnson, the second largest orthopedic business worldwide. Dr. Binette led several innovative regenerative medicine combination product development initiatives from bench top to approved clinical trials in US and Europe. Following JNJ, Dr. Binette joined the Spinal and Biologics business unit of Medtronic, the world’s largest medical device company, developing biologics, active devices and combination products for interventional spine procedures for back pain. Dr Binette received his PhD from Laval University in Québec City, followed with post-doctoral training at the Sanford-Burnham institute in La Jolla, and Harvard Medical School in Boston.

Chief Executive Officer, Cell Cure Neurosciences

Rami Skaliter, M.Sc., Ph.D.

Rami Skaliter, M.Sc., Ph.D., is the CEO of Cell Cure Neurosciences, a majority-owned (>95%) Israeli subsidiary of Lineage. The site is focused on manufacturing and related research and development activities. Dr. Skaliter was appointed in June 2017. In his last position, Dr. Skaliter worked for ten years as the Chief Operating Officer of Quark Pharmaceuticals, a late-stage pharmaceutical company developing siRNA-based novel therapeutics. Previously, Dr. Skaliter held various corporate and research executive positions at Quark Pharmaceuticals. Dr. Skaliter obtained his B.Sc. in Biology at the Ben-Gurion University and his M.Sc. and Ph.D. in Biochemistry at the Weizmann Institute in Israel. He specialized in the biochemistry of replication and mutagenesis mechanisms. Between 1993 and 1995, prior to joining Quark, Dr. Skaliter completed a post-doctoral fellowship at Stanford University. Dr. Skaliter serves as a director of Tikcro Technologies Ltd., a public company developing therapeutic antibodies.